ScienceAlert reports the injection destroys fat cells directly, and researchers see it as a possible way to keep weight off once GLP-1 treatment ends.
Recap by typeshit. Post by @sciencealert on Instagram.
He says close to 40% of weight lost in the trial's body-scan group was lean mass, and argues muscle loss isn't the drug's fault.
Wayne Pratt walks through what happens in the brain when drugs like Ozempic dial down the constant background chatter about eating.
Bikman cites a trial where people who lost about 21% and switched to placebo regained 14% within a year, while those who stayed on kept losing.
In Genome Medicine, diet-triggered delivery beat constant secretion on fat and liver fat, and kept down gut microbes carrying GLP-1-degrading peptidase genes.
Revenue rose 48% on Mounjaro and Zepbound demand, and Lilly raised 2026 guidance to $85B to $87B. CEO David Ricks calls retatrutide the next growth driver.
Amy Maxmen of KFF Health News looks at experimental peptides being pushed on longevity and optimization podcasts, and why she finds a lot of those claims misleading.
Loading…